SELECTA BIOSCIENCES INC (SELB) Stock Price, Forecast & Analysis
NASDAQ:SELB • US8162121045
SELB Key Statistics, Chart & Performance
The current stock price of SELB is 0.8812 USD. In the past month the price decreased by -21.32%. In the past year, price decreased by -37.06%.
SELB Technical Analysis
SELB Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to SELB. SELB may be in some trouble as it scores bad on both profitability and health.
SELB Financial Highlights
Over the last trailing twelve months SELB reported a non-GAAP Earnings per Share(EPS) of -0.22. The EPS decreased by -237.5% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -25.12% | ||
| ROE | -53.55% | ||
| Debt/Equity | 0.21 |
SELB Forecast & Estimates
12 analysts have analysed SELB and the average price target is 3.57 USD. This implies a price increase of 305.13% is expected in the next year compared to the current price of 0.8812.
For the next year, analysts expect an EPS growth of -228.11% and a revenue growth -72.53% for SELB
SELB Ownership
SELB Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.67 | 390.397B | ||
| AMGN | AMGEN INC | 16.25 | 197.396B | ||
| GILD | GILEAD SCIENCES INC | 17.02 | 193.298B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.81 | 117.026B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.87 | 81.87B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 46.05 | 42.576B | ||
| INSM | INSMED INC | N/A | 31.656B | ||
| NTRA | NATERA INC | N/A | 29.322B | ||
| BIIB | BIOGEN INC | 12.85 | 28.06B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.16 | 20.49B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About SELB
Company Profile
Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company is headquartered in Watertown, Massachusetts. The company went IPO on 2016-06-22. The firm leverages its ImmTOR platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. The company enables the re-dosing of life-saving gene therapies and restoring self-tolerance in autoimmune diseases. The ImmTOR platform reduces the formation of anti-drug antibodies (ADAs), against biologic drugs and restore self-tolerance to auto-antigens in autoimmune diseases. ImmTOR leverages nanoparticle technology to target rapamycin, an immunomodulatory drug, to antigen presenting cells to generate antigen-specific immune tolerance when combined with the antigen of interest. Its nanoparticles are designed to remain intact after injection into the body and accumulate predominantly in lymph nodes, the spleen, and the liver, where the immune response is coordinated. Its product candidate, SEL-212, which is in Phase III clinical development includes pegadricase, a pegylated uricase enzyme.
Company Info
SELECTA BIOSCIENCES INC
65 Grove Street
Watertown MASSACHUSETTS 02472 US
CEO: Carsten Brunn
Employees: 58
Phone: 16179231400.0
SELECTA BIOSCIENCES INC / SELB FAQ
What does SELB do?
Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company is headquartered in Watertown, Massachusetts. The company went IPO on 2016-06-22. The firm leverages its ImmTOR platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. The company enables the re-dosing of life-saving gene therapies and restoring self-tolerance in autoimmune diseases. The ImmTOR platform reduces the formation of anti-drug antibodies (ADAs), against biologic drugs and restore self-tolerance to auto-antigens in autoimmune diseases. ImmTOR leverages nanoparticle technology to target rapamycin, an immunomodulatory drug, to antigen presenting cells to generate antigen-specific immune tolerance when combined with the antigen of interest. Its nanoparticles are designed to remain intact after injection into the body and accumulate predominantly in lymph nodes, the spleen, and the liver, where the immune response is coordinated. Its product candidate, SEL-212, which is in Phase III clinical development includes pegadricase, a pegylated uricase enzyme.
What is the current price of SELB stock?
The current stock price of SELB is 0.8812 USD. The price decreased by -8% in the last trading session.
Does SELB stock pay dividends?
SELB does not pay a dividend.
What is the ChartMill rating of SELECTA BIOSCIENCES INC stock?
SELB has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is SELECTA BIOSCIENCES INC worth?
SELECTA BIOSCIENCES INC (SELB) has a market capitalization of 135.20M USD. This makes SELB a Micro Cap stock.
Who owns SELECTA BIOSCIENCES INC?
You can find the ownership structure of SELECTA BIOSCIENCES INC (SELB) on the Ownership tab.